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Abstract
Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense
mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes
cause similar neuropathies, although the underlying mechanisms are not fully understood. To address this, we generated
transgenic mice that ubiquitously over-express wild-type GARS and crossed them to two dominant mouse models of
CMT2D to distinguish loss-of-function and gain-of-function mechanisms. Over-expression of wild-type GARS does not
improve the neuropathy phenotype in heterozygous Gars mutant mice, as determined by histological, functional, and
behavioral tests. Transgenic GARS is able to rescue a pathological point mutation as a homozygote or in complementation
tests with a Gars null allele, demonstrating the functionality of the transgene and revealing a recessive loss-of-function
component of the point mutation. Missense mutations as transgene-rescued homozygotes or compound heterozygotes
have a more severe neuropathy than heterozygotes, indicating that increased dosage of the disease-causing alleles results
in a more severe neurological phenotype, even in the presence of a wild-type transgene. We conclude that, although
missense mutations of Gars may cause some loss of function, the dominant neuropathy phenotype observed in mice is
caused by a dose-dependent gain of function that is not mitigated by over-expression of functional wild-type protein.
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Introduction
Charcot-Marie-Tooth disease (CMT) is a heterogeneous group
of inherited neuropathies affecting approximately 1 in 2,500
people [1]. CMT is divided into type 1 forms, characterized by
demyelination and decreased nerve conduction velocity, type 2 or
axonal forms, characterized by axon loss and reduced evoked
potential amplitudes, and intermediate forms having features of
both demyelinating and axonal neuropathy [2,3].
As the genetic causes of CMT have been identified, shared
mechanisms have been elucidated that help explain the myelin
degeneration in CMT type 1 and axon degeneration in CMT type 2.
Disruption of myelin structure through mutation of proteins
produced by peripheral Schwann cells is a recurring mechanism in
type 1 CMTs [4–6]. Defects associated with vesicle trafficking [7,8],
mitochondrial morphology [9–11], and cytoskeletal integrity [12,13]
have each been implicated in multiple axonal forms of CMT.
Other axonal and intermediate CMTs have been linked to
mutations in tRNA synthetase genes. The first to be identified and
best characterized is CMT type 2D, caused by mutations in the
glycyl-tRNA synthetase gene (GARS, MIM ID 601472) [14].
Subsequently, mutations in tyrosyl-tRNA synthetase (YARS, MIM
ID 608323) were identified in patients with dominant intermediate
CMTC [15]; a single missense change in the alanyl-tRNA
synthetase gene (AARS, MIM ID 613287) was associated with
axonal CMT2N [16]; and most recently compound heterozygous
frame shift/missense mutations in the lysyl-tRNA synthetase gene
(KARS, MIM ID 613641) were reported in a patient with recessive
intermediate CMTB [17]. While human genetic studies have
implicated mutations in multiple tRNA synthetase genes, the
pathogenic mechanism for these neuropathies is still unclear,
although a shared mechanism is an attractive hypothesis [18]. In
particular, it is unclear whether the mutations result in a
pathological gain of function, a partial loss of activity related to
PLoS Genetics | www.plosgenetics.org 1 December 2011 | Volume 7 | Issue 12 | e1002399translation, an impact on an unknown, noncanonical activity, or a
combination of these mechanisms.
tRNA synthetases covalently link tRNAs with their cognate
amino acids to translate the genetic code. These enzymes serve an
essential, nonredundant role in protein synthesis. It has been
suggested that a reduction of this tRNA-charging function could
result in neuropathy, and peripheral nerves with long, large-
diameter axons may be especially vulnerable to decreased activity
because of their unusual transport and metabolic demands
[15,19]. Consistent with this, several disease-causing mutations
in GARS are associated with a reduction in charging function in
cell-free assays, and this is roughly correlated with a decreased
ability to rescue nonviability in yeast caused by deficiency of GRS1,
the ortholog of GARS. However other mutations do not impair this
function [19–21].
Structural studies have shown that many of the mutations alter
dimer association, affecting homodimer formation that is essential
for tRNA-charging activity [20,22]. Furthermore, all mutations
tested alter the subcellular distribution of GARS in transfected
cells, also suggesting a possible loss of function at the cellular level
through mislocalization, even if charging activity is preserved [19–
21,23,24].
Two mouse models of CMT2D that share pathological features
with the human disease, with differing severity, are caused by
dominant amino acid substitutions in Gars. The Gars
Nmf249 allele
(hereafter abbreviated Nmf249) causes reduced body weight and
impaired mobility in heterozygous mice [25]. Axon number and
neuromuscular junction (NMJ) morphology are normal at post-
natal day 7, but subsequently axons are lost without a reduction in
myelin thickness; NMJs show partial and sometimes complete
denervation. The Nmf249 allele is an insertion in the Gars gene that
substitutes lysine and tyrosine for proline at position 278 in the
mouse GARS protein, equivalent to a P234KY change in human
GARS (Note: numbering differences are because the human
annotation does not consider the N-terminal mitochondrial
localization signal appended through alternative start codon
usage).
The Gars
C201R allele (hereafter abbreviated C201R) is less severe
and was identified in a chemical mutagenesis screen. In addition to
impaired grip strength, these mice have impaired motor control,
diminished muscle force, reduced weight, a shift towards smaller
axon diameters, and some muscle denervation [26]. The mouse
C201R substitution is equivalent to C157R in human GARS.
These two alleles demonstrate the spectrum of phenotypic severity
in mice and provide a range of tests that can be used to quantify
the effects on neuromuscular function.
Previous studies in mice are consistent with either a pathological
gain-of-function for the mutant protein, or a partial loss-of-
function, or both. Mouse and human mutations both cause
dominantly inherited neuropathy. Moreover, mice heterozygous
for a gene trap allele (Gars
XM256/+, a presumed null allele, hereafter
abbreviated XM256) do not have a phenotype, arguing against a
simple loss-of-function and ruling out haploinsufficiency as a cause
of the neuropathy phenotype [25]. As expected for a gene with
such a critical activity, homozygous gene trap mice die as embryos.
Mice homozygous for the C201R allele are more severely affected
than heterozygotes of either mutant allele and die at about two
weeks of age [26]. This increased severity may be the result of
doubling a pathological gain of function associated with the
C201R protein, or the inability of the mutant protein to actively
perform its normal function, or a combination of these effects.
Consistent with the inability of the mutant protein to sustain its
normal function, both the C201R and the Nmf249 mutations fail to
complement the loss-of-function XM256 allele, resulting in
embryonic death in the absence of wild-type protein, without an
increase in the genetic dosage of the mutant allele [25,26]. The
embryonic death of these mice may indicate that wild-type GARS
is mitigating a toxic gain of function, or that the mutant proteins
do not retain their normal function, or it may indicate a
combination of these mechanisms.
We hypothesized that a partial loss-of-function could be
corrected by transgenic over-expression of a functional wild-type
GARS protein, whereas a pathological gain-of-function could be
independent of wild-type activity and therefore would not
necessarily be corrected by increased wild-type expression. In
order to determine whether increased wild-type GARS rescues the
Gars mutant mice, we crossed transgenic mice that over-express
the wild-type human GARS gene to both the Nmf249/+ and
C201R/+ mice, and analyzed the effects on the phenotype. We
found a recessive reduction in perinatal viability in C201R as a
homozygote or in combination with the XM256 gene trap allele,
which could be rescued by wild-type GARS over-expression.
However, wild-type over-expression did not substantially mitigate
the neuropathy phenotype in heterozygous Nmf249/+ or C201R/+
mice, consistent with a predominant gain of function as the cause
of peripheral neuropathy in these mice.
Results
Transgenic mice over-expressing human GARS
Wild-type human GARS was expressed in mice using a
transgene construct with the full-length human GARS open
reading frame under the control of a CAG promoter [27], which
is a fusion of the CMV early enhancer and the chicken b actin
promoter and leads to strong ubiquitous transcription of
downstream elements (Figure 1A). Two independent transgene
founder strains, designated Transgene A (TgA) and Transgene D
(TgD), were identified and used in this study. These two lines over-
express GARS in spinal cord and sciatic nerve at similar levels
(.10 times endogenous levels), as measured by immunoblotting
(Figure 1B).
Transgenic GARS is expressed in myelinating Schwann
cells and sciatic nerve axons
In order to examine in situ expression of the transgenic protein
in relevant cell types, we excised and fixed the sciatic nerve and
Author Summary
Mutations in the glycyl-tRNA synthetase gene (GARS) cause
Charcot-Marie-Tooth disease type 2D, a disease character-
ized by neuronal axon loss in the arms and legs, resulting
in weakness and sensory problems. The GARS protein is
essential for protein synthesis in every cell, and it has been
difficult to determine whether the mutations result in
disease because they impair this function or whether GARS
somehow becomes toxic when it is mutated. We
generated mice that overexpress normal GARS and mated
these to two different mouse models of the disease to
determine whether a restoration of normal function could
prevent the disease. These crosses demonstrated that the
mutant forms of GARS are toxic, and this toxic effect
increases as the amount of mutant protein increases.
Furthermore, this toxicity cannot be reduced or prevented
by providing additional normal GARS. Therefore, these
results suggest that, for most patients, therapies need to
specifically target the mutant form of GARS or the toxic
function.
Gain and Loss of Function with Gars Mutations
PLoS Genetics | www.plosgenetics.org 2 December 2011 | Volume 7 | Issue 12 | e1002399Figure 1. The CAG-GARS transgenic construct is robustly expressed in tissues and cell types affected by CMT. (A) The wild-type GARS
transgene construct contains a CAG promoter, followed by an intron, and the full-length GARS cDNA, including the N-terminal mitochondrial
localization signal, with flanking 59 and 39 UTR sequence. These elements were between two insulator sequences (INS). (B) Immunoblotting with anti-
GARS confirmed that transgenes A and D express at similar levels, both above the level of FVB/N wild-type mice in spinal cord and sciatic nerve. Anti-
b actin was used as a loading control. (C) Confocal images of teased fiber preparations from sciatic nerve stained with neurofilament and GARS
antibodies from one-month-old animals. All three red channel images (GARS staining) were matched for laser intensity, gain, and the Z depth of field
(scale bars are 40 mm). To confirm that transgenes A and D were overexpressed in these tissues, exposure-matched analysis was performed on FVB/N
control mice (n=3), TgA mice (n=3) and TgD mice (n=3). F1 mice with the transgenes overexpress GARS in sciatic nerve and spinal cord. We crossed
Nmf249/+ mice with WT; TgD mice and analyzed F1 progeny in all of the four resulting genotypes. Western blot was used to evaluate expression in
the spinal cord (D) and in the sciatic nerve (E). On both wild-type and mutant backgrounds, the transgene overexpresses wild-type GARS in these
tissues. F) Aminoacylation activity for alanyl tRNA synthetase (AARS) was not different between wild type (black) and WT;TgA (red) spinal cord
homogenates. G) Spinal cord homogenates from WT;TgA mice showed much higher (.10 fold) aminoacylation activity when assayed for GARS
activity. Three wild type and four TgA littermates were tested at nine weeks of age.
doi:10.1371/journal.pgen.1002399.g001
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allow visualization of individual axons.
Endogenous GARS is present at low levels in the sciatic nerve
(Figure 1C and [21]). In exposure-matched confocal images, anti-
GARS staining was increased in animals with either TgA or TgD
over the endogenous levels in strain matched FVB/N control mice
without the transgene. The pattern of GARS immunoreactivity in
transgenic mice was also similar to that of wild type mice, with
staining found in both the axon and Schwann cells, suggesting the
transgenic protein localizes normally (Figure 1C). Therefore, the
transgenes produce protein that is present in Schwann cells and
transported to peripheral axons, as indicated by overlapping
neurofilament staining.
Over-expression of wild-type GARS does not reduce axon
loss in Nmf249/+ mice
To examine the effect of over-expressing wild-type GARS on the
neuropathy phenotype, the more severe Nmf249/+ mice were
crossed with hemizygous transgenic mice and the four resulting F1
genotypes were analyzed: wild type, WT; Tg, Nmf249/+, and
Nmf249/+;T g . The mice were analyzed at post-natal day 30 (P30).
Mice with the transgene had much stronger levels of GARS
protein expression than non-transgenic littermates in spinal cord
and sciatic nerve on immunoblots of animals with both wild-type
and Nmf249/+ backgrounds (Figure 1D, 1E). Transgene expres-
sion was confirmed by immunoblot in mice with each genotype for
crosses with both Nmf249/+ and C201R/+ (Figure S1). There was
no difference overall in GARS levels between wild type and
Nmf249/+ or C201R/+, however, both transgenic strains result in
expression well above endogenous levels. Consistent with the
increased GARS protein, aminoacylation activity was also
increased, indicating the transgenic protein is enzymatically active.
Homogenates from the spinal cord of wild type and WT;TgA and
TgD mice were prepared and assayed for the activity of both
GARS and alanyl tRNA synthetase (AARS) as an internal control.
As anticipated, no increase in activity was seen for AARS
(Figure 1F), whereas GARS activity was increased at least 10 fold
(as judged by the initial rate of tRNA glycylation) in each
transgenic strain (Figure 1G and data not shown).
To assess the effect of the transgenic GARS on peripheral
neuropathy, we examined the femoral nerve, which consists of a
primarily motor branch innervating the quadriceps, and a
primarily sensory branch that becomes the saphenous nerve and
innervates the skin of the lower leg. In Nmf249/+ mice, both
branches had a reduction in myelinated axon number, whereas
C201R/+ mice had normal axon numbers [25,26]. We isolated
motor and sensory branches of the femoral nerve from F1 progeny
from our cross between Nmf249/+ mice and GARS wild-type
transgenic mice at one month of age. The nerves were fixed and
embedded, and semi-thin sections were stained with toluidine blue
for quantification of axon number and size (Figure 2A–2L). In
these cross sections, the size of the femoral nerves was reduced in
the presence of the Nmf249/+ allele (Figure 2A–2F compared to
Figure 2G–2L). This was quantified by counting myelinated
axons, which showed on average a 26% reduction in axons in
motor nerves with the Nmf249/+ allele compared to wild-type
littermates. There was no significant improvement in the Nmf249/
+ axon numbers in motor or sensory nerves in mice with TgA or
TgD (Figure 2M).
We next examined the distribution of motor axon diameters to
determine whether there was any improvement in motor nerve
pathology that was not detected with the axon counts. A
cumulative histogram of the frequency of observed axon diameters
shows the distribution and range of axon diameters in this study.
The plot shows a marked shift from large diameter axons (4–6 mm)
to small diameter axons (0–3 mm) in Nmf249/+ mice (Figure 2N).
Both TgA and TgD showed small but significant improvements in
axon diameter in Nmf249/+ mice by a nested-ANOVA analysis
(p=0.006). There was no impact of either transgene on axon
diameter in an otherwise wild-type background. With and without
the transgene, the Nmf249 allele significantly reduced mean axon
diameter, while the proportional observed decrease in myelin
thickness is not as dramatic (Figure S2).
Nerve conduction and body weight are not improved by
over-expression of wild-type GARS
Consistent with the slight improvement in axon diameters
observed in Nmf249/+ mice with TgA and TgD (Figure 2N), there
was trend towards improvement in nerve conduction velocity, but
this was not significant. Nerve conduction in Nmf249/+ mice is
significantly reduced to approximately 25% of wild-type velocities.
Nmf249/+; TgA and Nmf249/+; TgD mice had NCVs that did not
differ significantly from Nmf249/+ alone (Figure 3A).
Previous studies show that between 2 and 4 weeks of age, mice
with the Nmf249/+ allele stop gaining weight and become
significantly smaller than littermate controls [25]. Various factors
are likely to contribute to the decreased weight. Denervation
decreases muscle mass and probably compromises ability to feed.
As a measure of overall health, we weighed the mice in this study.
Consistent with measures of peripheral nerve function, mutant
mice with TgD trended toward being heavier, but neither TgA nor
TgD significantly improved the body weights of Nmf249/+ mice,
and all mutant animals were still significantly lighter than
littermate control mice (Figure 3B).
GARS over-expression does not improve neuromuscular
junction occupancy in CMT2D mice
The loss of motor axons in peripheral nerves of Nmf249/+ mice
also results in a disruption of the neuromuscular junction (NMJ).
Mature, healthy motor neurons innervate muscle with pretzel-
shaped presynaptic terminals. During development, post-synaptic
regions mirror the shape of the axon terminal in regions of
specialization where acetylcholine receptors concentrate to define
the muscle side of the NMJ. The loss of distal motor axons is
reflected in the NMJs of Nmf249/+ mice, which are severely
dysmorphic. Many junctions in mutant mice are partially or
completely denervated by post-natal day 30 [25]. To further study
whether over-expression of GARS affects the motor phenotype in
CMT2D mice, we looked at NMJ morphology and occupancy.
NMJs from wild-type mice with and without the transgene had
normal ‘‘pretzel-like’’ morphology with full overlap between pre-
and post-synaptic terminals (Figure 4A–4C). In mutant mice
(Figure 4D), there are regions where the presynaptic markers are
absent in areas where there is post-synaptic staining (arrowheads).
There are also post-synaptic junctions that have no associated
nerve terminal, indicating that the muscle fiber has been
denervated (arrows). The morphology and occupancy of NMJs
in Nmf249/+; TgA mice (Figure 4E) and Nmf249/+; TgD (Figure 4F)
were not improved. In each animal, NMJs were scored based on
the overlap between pre- and post-synaptic markers and classified
as fully innervated, partially denervated, or fully denervated. This
assessment of NMJ occupancy showed there was no significant
improvement in mutant mice with transgenes over mutant mice
without transgenes (Figure 4G). Therefore, with the exception of a
slight increase in axon diameters, the over-expression of wild type
GARS as a transgene did not lead to significant improvements in
any phenotypic measure in the Nmf249/+ mice.
Gain and Loss of Function with Gars Mutations
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in C201R/+ mice
To further substantiate these findings, we also tested the effects
of both TgA and TgD in a second pathological Gars allele. The
milder CMT2D disease model, C201R/+, has less severe overt
neuromuscular phenotypes than the Nmf249/+ mice. In this
model, behavioral measures of peripheral nerve dysfunction are
useful to detect the subtler phenotype. One behavioral measure is
a wire hang test of grip strength. Mice were placed on a wire grid
that was then inverted and the time that mice were able to suspend
themselves was recorded. At 3 and 6 weeks of age, wild-type mice
are often able to hang for a full minute, when the test is stopped.
Neither transgene significantly improved performance on this test
at either age tested (Figure 5A–5D).
To look for subclinical improvements in motor unit function, we
tested nerve conduction on mice from this cross as well. Nerve
conduction in C201R/+ mice is significantly reduced to approx-
imately 55% of wild-type levels. Neither TgA nor TgD
significantly improved NCVs in the C201R/+ mice (Figure 5E,
5F).
In summary, there were trends towards slight and variable
improvements in body weight, axon diameter, and NCV in
CMT2D mouse models when wild-type GARS is ubiquitously over-
expressed, but none of these improvements were statistically
significant, and the mice still have compromised motor function
assessed by behavioral, histological, and electrophysiological
measures compared to control animals.
Wild-type GARS transgenes functionally substitute for an
endogenous wild-type Gars allele
Although there was a robust increase in wild-type GARS
protein detected by immunoblotting in both TgA and TgD, and
animals with the transgenes had significantly higher tRNA
Gly
charging activity, it remained to be demonstrated that the
transgene products in these mice can substitute for a loss of
wild-type Gars. Human GARS can functionally replace the fruit fly
ortholog, Aats-gly [28], but does not rescue yeast lacking GRS1
(A.A. unpublished data). To confirm that our human GARS
transgene could replace mouse Gars, we tested whether the
transgenes could restore wild-type function in place of the XM256
loss-of-function gene trap allele [25]. The XM256 allele unam-
biguously causes a loss-of-function by intercepting splicing and
reducing mRNA levels of Gars assayed by northern blot, as well as
reducing enzymatic activity in tissue homogenates from heterozy-
gous mice [25].
Compound heterozygotes of the gene trap allele with either
mutant allele (C201R/XM256 and Nmf249/XM256) die embry-
onically [25,26]. We crossed XM256/+; TgA or TgD mice with
C201R/+ mice, and the offspring included both viable C201R/
XM256; TgA and C201R/XM256; TgD mice. This shows that both
TgA and TgD were able to restore viability by substituting for the
endogenous wild-type Gars allele. We expected C201R/XM256; Tg
mice to have a mild neuropathy because of the pathogenic C201R
allele, and ‘‘full rescue’’ would therefore constitute viable mice
with a phenotype comparable to C201R/+.
Chi-square analysis showed that C201R/XM256; TgA and
C201R/XM256; TgD mice were born at expected Mendelian
ratios (6/48, p=1.0, and 4/63, p=0.14, respectively), while
C201R/XM256 mice without the transgenes were not viable, as
expected, and represented a significantly absent class (p=0.009,
p=0.003, respectively).
In addition to restoration of viability, the C201R/XM256 mice
with the transgenes were restored to a C201R/+-like neuropathy.
The rescued mice had femoral nerve pathology and axon numbers
that were not significantly different from C201R/+ mice or
controls at eight weeks of age (Figure 6A–6J, 6L). As previously
reported, neither the XM256/+ nor the C201R/+ mice had a
decrease in myelinated axon number in the motor or sensory
branch of the femoral nerve, whereas the Nmf249/+ mice do have
reduced axon numbers (Figure 6 and [25,26]). Therefore, the
rescued mice do not show an increased severity in their
neuropathy by this measure. We also tested this functionally by
measuring nerve conduction velocities, which are normal in
XM256/+ mice (Figure 6K), but are significantly reduced in
C201R/+ mice (Figure 5E and 5F, Figure 6K). Conduction
velocities in rescued mice were significantly below control values,
and were not significantly different than C201R/+ values.
To further verify that the transgenes fully rescued the
neuropathy to the severity anticipated for C201R/+, we also
examined NMJ morphology and occupancy at 8 weeks of age. The
NMJs of XM256/+ mice are indistinguishable in morphology and
occupancy from wild-type mice (Figure 7A and not shown), and
form complex pretzel structures with complete overlap between
pre and post-synaptic markers. NMJs in C201R/+ mice (Figure 7B)
have regions of immature morphology or denervation that are
noticeably different from wild-type, but are not as dysmorphic as
the NMJs in Nmf249/+ mice. C201R/XM256 mice with TgA or
TgD had neuromuscular junction morphology similar to that of
C201R/+ mice (Figure 7C, 7D). No significant difference in the
proportion of NMJs that were fully occupied was observed
between C201R/+, C201R/XM256; TgA, and C201R/XM256;
TgD mice (Figure 7E).
While the severity of the neuropathy was the same in C201R/+
and C201R/XM256; Tg mice, the rescued mice had significantly
lower body weights than wild type or XM256/+ animals (Figure
S3A). The muscle weight/body weight ratio was not reduced in
Figure 2. Neither motor nor sensory axon loss in Nmf249/+ mice is abated by transgenes A or D. Semi-thin sections of motor and sensory
branches of the femoral nerve collected from one month old mice were stained with Toluidine Blue. Representative images are shown in (A-L)(scale
bar in J is 100 mm and higher magnification insets are 30630 mm). (M) Myelinated axons were counted in femoral nerves. Axon counts in the motor
nerves were decreased from 587632 (n=12) in wild type mice to 435626 (n=9) in Nmf249/+ (p,0.001). Wild type mice with TgA and TgD had motor
axon counts of 579629 (n=11) and 614622, respectively and were not statistically different from counts in wild type mice. Nmf249/+ mice with TgA
had motor axon counts of 441643 (n=5) and with TgD had motor axon counts of 438652 (n=5), which were not significantly different compared to
Nmf249/+ mice. Mice with the mutant allele all had significantly reduced motor axon counts when compared to any of the wild type groups
(p,0.001). Myelinated axon numbers in the sensory nerves were significantly (p,0.001) decreased from 876683 (n=12) for wild type mice to
654694 (n=9) for Nmf249/+. Wild type mice with TgA and TgD had sensory axon counts of 842664 (n=11) and 885689 (n=6), respectively, and
were not statistically different from wild type mice. Nmf249/+ mice with TgA had motor axon counts of 7306118 (n=5), Nmf249/+ mice with TgD had
motor axon counts of 758677 (n=5). Transgenes A and D did not significantly alter sensory axon number compared to Nmf249/+ alone, but were
somewhat intermediate with Nmf249/+; TgA mice being modestly reduced relative to wild type controls (p,0.05), whereas TgD mice were not
different from controls. (N) A cumulative histogram shows the distribution of axon diameters in all six genotypes and demonstrates that there is a
shift to smaller axons in the mutant genotypes. There is an obvious clustering of WT, WT; TgA, and WT; TgD mice and Nmf249/+, Nmf249/+; TgA, and
Nmf249/+; TgD mice.
doi:10.1371/journal.pgen.1002399.g002
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of neuropathic muscle degeneration (Figure S3B). Therefore, the
reduced body weight probably reflects some insufficiency in
transgene expression in other tissues. However, the viability of
compound heterozygous C201R/XM256 mice with TgA and TgD
indicates that both produce functional protein and both are
capable of substituting for a wild type allele of Gars.
Increasing the genetic dosage of mutant Gars increases
the severity of neuropathy
To examine the effects of increasing the genetic dose of the
mutant alleles of Gars and to further parse if there is a loss-of-
function component to the amino acid substitutions, we generated
C201R homozygotes and C201R/Nmf249 compound heterozy-
gotes, both with and without TgD.
C201R homozygous mice have a more severe neuropathy
phenotype than C201R/+ heterozygotes, and typically die at about
two weeks of age [26]. It is unclear whether the more severe
phenotype in homozygotes is due to a double-dose of a toxic
mutant protein, to a compounded loss-of-function, or a combina-
tion of these effects. Based on the ability of TgD to substitute for a
wild type Gars allele in rescuing viability in combination with
XM256, we hypothesized that a loss of function would be
corrected by the presence of the transgene, whereas increased
toxicity from the higher dose of mutant protein would not be
corrected, based on the inability of the transgene to improve the
neuropathy phenotype in C201R/+ mice.
Consistent with previous reports, we found that C201R/C201R
mice were subviable (X
2 p=0.016) [26]. Only two homozygous
C201R mice were recovered in 69 offspring (1/8 anticipated), and
these died by P12 before they could be analyzed. However,
C201R/C201R; TgD mice were born at expected Mendelian ratios
(11/69, X
2 p=0.39), and consistently lived to post-natal day 17,
when tissues were collected and analyzed. The maximum observed
lifespan for these mice was to P20. Despite the restoration of wild-
type GARS function with TgD, these mice had a more severe
neuropathy than C201R/+ heterozygotes. The C201R/
C201R;TgD mice had approximately a 50% reduction in axon
numbers in the motor branch of the femoral nerve (Figure 8A, 8B,
8D, 8G), and the mice were ,5 grams in weight at P17
(Figure 8H). Neuromuscular junction defects were similarly
increased in severity (Figure 8I, 8J, 8L, 8M, 8P). At P17, wild-
type NMJs have developed into mature pretzel shapes, but
C201R/+ NMJs are arrested at a less-mature, plaque-like
morphology, and show an increased incidence of partially
innervated junctions. The C201R/C201R;TgD mice demonstrated
frank denervation at almost half of the postsynaptic sites. In
agreement with this, we could not obtain nerve conduction
velocities from these mice, because muscle action potentials were
too small to reliably record (n=8). Thus, the reduced viability
embryonically and in neonates seen in C201R homozygous mice
was corrected by the TgD, as demonstrated by the recovery of
C201R/C201R;TgD mice at the expected Mendelian ratios and
their survival to P17. However, the increased genetic dosage of the
C201R allele leads to a more severe neuropathy.
To further examine this effect of genetic dosage and apparent
recessive partial-loss-of-function, we also made compound hetero-
zygous C201R/Nmf249 mice. Interestingly, both C201R/Nmf249
and C201R/Nmf249; TgD mice were viable and born at expected
Mendelian frequencies (5/33, X
2 p=0.95 and 4/33, p=0.65,
respectively). Considering that both C201R/XM256 and Nmf249/
XM256 are nonviable in the absence of a wild-type transgene, the
viability of C201R/Nmf249 mice suggests that there is intragenic
complementation between the two mutant alleles that alleviates
the loss-of-function and subsequent reduction in viability at birth.
Like homozygous C201R/C201R; TgD mice, the motor branch
of the femoral nerve is noticeably smaller and axon numbers are
significantly reduced in C201R/Nmf249 and C201R/Nmf249; TgD
mice compared to wild-type or heterozygous littermate controls
(Figure 8A–8G). No significant difference in axon numbers was
seen between the C201R/C201R; TgD, C201R/Nmf249, and
C201R/Nmf249; TgD genotypes. The same qualitative and
quantitative differences were seen in the sensory nerves of these
animals (Figure S4).
The overall health and overt appearance of the compound
heterozygous mice was better than that of homozygous C201R/
Figure 3. Wild-type over-expression does not improve motor
nerve conduction and body weight in Nmf249/+ mice. (A) The
Nmf249/+ allele significantly reduces nerve conduction velocity (NCV) in
one-month-old mice from 33.966.7 m/s (n=8) measured in control
wild-type animals to 7.861.7 m/s (n=7) (p,0.001). Nmf249/+; TgA had
nerve conduction of 10.261.6 m/s (n=5) and Nmf249/+; TgD had
velocities of 12.363.0 m/s (n=3), which were not significantly different
than Nmf249/+. Compared to wild-type, all three mutant genotypes had
significantly reduced NCVs (p,0.001). WT; TgA and WT; TgD NCVs were
not significantly different from wild-type mice: 32.065.4 (n=8) and
29.362.8 (n=6), respectively. (B) As an indicator of overall health, body
weight was measured at P30. Wild-type mice weighed 18.162.6 g
(n=8) and were not significantly different from WT; TgA mice, which
weighed 19.561.8 g (n=6), and WT; TgD mice that weighed 19.061.6 g
(n=6). Compared to wild type mice, Nmf249/+ mice were significantly
lighter, weighing 10.161.4 g (n=8)(p,0.001). Nmf249/+; TgA and
Nmf249/+; TgD mice were not significantly different than nontransgenic
mutant mice with a mean weight of 11.660.8 g (n=5) and 12.960.5 g
(n=3) respectively.
doi:10.1371/journal.pgen.1002399.g003
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C201R/Nmf249; TgD mice were significantly lower than C201R/+
mice (Figure 8H), and C201R/C201R; TgD weighed significantly
less than C201R/Nmf249 mice.
Morphological changes seen in the neuromuscular junctions of
C201R/Nmf249 and C201R/Nmf249; TgD mice were also more
severe than either allele as a heterozygote and reflected the axon
loss seen in the femoral nerves. Like C201R/+ mice at P17,
Nmf249/+ mice have partially denervated NMJs (Figure 8K) with
areas of disorganized post-synaptic staining, but also more
examples of complete denervation. Like the C201R/C210R;TgD
mice, compound heterozygotes with or without TgD had even
more dysmorphic NMJ morphology than Nmf249/+ heterozy-
gotes, with a majority of NMJs that were partially or fully
denervated and very few that were fully innervated (Figure 8N–
8P). There were significantly more denervated NMJs in C201R/
C201R; TgD, C201R/Nmf249, and C201R/Nmf249; TgD mice
compared to Nmf249/+ mice (Figure 8P). Compound muscle
action potentials were again too small to reliably record in C201R/
Nmf249 (n=4), and C201R/Nmf249; TgD (n=5) mice.
Therefore, the presence of TgD did not alter viability, axon
number, body weight, or NMJ occupancy of the compound
Figure 4. Neuromuscular junction morphology and occupancy. Neuromuscular junctions (NMJs) from plantaris muscles were collected from
one-month-old mice and visualized with antibodies labeling neurofilament (NF) and synaptic vesicle protein 2 (SV2) (green), and a-bungarotoxin,
which binds acetylcholine receptors (AChRs) (red). NMJs from (A) wild type, (B) WT; TgA, and (C) WT; TgD mice were fully occupied by presynaptic
terminals that completely overlap signals from postsynaptic markers with a complex, pretzel-like morphology. D) Nmf249/+, (E) Nmf249/+; TgA, and
(F) Nmf249/+; TgD mice have NMJs with regions of post-synaptic staining that are not innervated (arrowheads) and some post-synaptic NMJs have no
associated nerve (arrows). (G) The occupancy of NMJs was quantified by scoring as fully innervated, partially denervated or fully denervated, based on
the overlap between pre- and post-synaptic staining. 96.762.1% of wild-type NMJs were fully innervated, while only 19.669.3% were fully innervated
in Nmf249/+ mice (p,0.001). No significant change was seen between mutant mice and mutant mice with transgenes A and D, where 14.565.9% and
25.5612.8% of NMJs were fully innervated, respectively. All scale bars are 20 mm.
doi:10.1371/journal.pgen.1002399.g004
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improving the recessive loss-of-function sub-viability phenotype
observed in C201R homozygotes. In both C201R/Nmf249
compound heterozygotes and C201R homozygotes, the severity
of the neuropathy increases as the genetic dosage of the mutant
Gars increases, even in the presence of the wild-type transgene.
Discussion
Tosummarizeourresults,the over-expressionoffunctional,wild-
type GARS does not suppress the neuropathy caused by dominant
amino acid substitutions, but does rescue reduced viability seen with
homozygouspoint mutationsorinpoint mutationscombined witha
null allele. Furthermore, the neuropathy is worsened with
homozygous or compound heterozygous amino acid substitution
alleles (Table 1). From these results we conclude that the dominant
mechanism underlying GARS mutations and the degeneration of
peripheral axons is a toxic gain of function by the mutant GARS
protein. This toxicity depends on the dosage of the mutant protein
andisnot mitigatedorout-competedbytheover-expression ofwild-
type GARS, suggesting that the neuropathy is not likely to be caused
by a loss-of-function or a simple dominant-negative mechanism.
There is also a loss of GARS function with the mutations, but this is
only seen when alleles with amino-acid changes are made
homozygous or placed over a loss-of-function allele created by a
gene trap insertion. The recessive loss of function reduces viability,
but is corrected by the transgenic over-expression of wild-type
GARS, leaving these mice with only the dose-dependent neuropathy
caused by expression of the mutant protein. Interestingly,
compound heterozygous mice carrying two different alleles with
pathological amino-acid changes show ‘‘additive’’ neuropathy that
is more severe than either allele alone as a heterozygote, and is
comparable in severity to a point mutation as a homozygote.
However, compound heterozygous mice do not show reduced
neonatal viability associated with a loss of function, and the
phenotype is not improved by over-expression of wild-type GARS,
indicating that there is intragenic complementation and little or no
loss of function in the compound heterozygotes. The basis for these
conclusions and the implications for CMT are discussed below.
Peripheral neuropathy phenotype is caused by a gain of
function
Overall, no significant improvement in axonopathy phenotypes
was seen in CMT2D model mice over-expressing wild-type
GARS. Two transgenes with similar levels of expression were
used in these crosses and yielded effectively the same results.
Neither transgene prevented axon degeneration or improved
nerve conduction velocity or NMJ morphology and occupancy in
the Nmf249/+ mice at one month of age. The only positive effect
of the transgenes was a minor improvement in axon diameter.
Similarly, neither transgene improved behavioral measures at
three or six weeks of age, or NCVs at eight or twelve weeks of age
in C201R/+ mice. Thus, over-expression of wild-type GARS did
not suppress the dominant neuropathy phenotype. It is also
notable that the over-expression of wild-type GARS did not cause
any phenotype on its own in either transgenic line.
These crosses, and the observation that XM256/+ mice do not
have a neuropathy, show that the mutant protein itself is toxic and
causes peripheral nerve degeneration. The toxicity can be
intensified, and the neuropathy worsened, by increasing the dose
of mutant protein in either homozygotes or compound heterozy-
gotes. Lifespan, NMJ occupancy, axon numbers and body weight
are significantly reduced in C201R/Nmf249, C201R/Nmf249; TgD,
and C201R/C201R; TgD mice below the levels of Nmf249/+ and
C201R/+ mice, which only have one copy of the mutant protein.
This is consistent with experiments with YARS in Drosophila, which
also indicate that the mutant tRNA synthetase has a dose-
dependent toxicity [29].
Loss-of-function component is responsible for reduced
viability
Although the peripheral axon degeneration is caused by toxicity
of the mutant protein, the mutations do have loss-of-function
characteristics. Homozygous C201R mice are subviable, and
neither allele is viable in combination with the gene trap allele,
despite the Nmf249/+ P278KY protein being fully active in cell-
free activity assays of amino acylation and tRNA charging [25].
The embryonic lethality observed in these Gars alleles is
probably not related to the neuropathy phenotype. In fact, a
functioning nervous system is not required during embryonic
development. Mice deficient for proteins that are crucial for the
function of the central and peripheral nervous system are born in
the anticipated numbers, but do not survive independently after
birth [30–32]. GARS is necessary for translation in every cell, and
loss of function in non-neurological tissue is a likely cause of the
embryonic lethality.
With transgenic over-expression of wild-type protein, we were
able torestorefullviabilitytoC201R/XM256mice,whichotherwise
die embryonically, and C201R/C201R mice, which are otherwise
subviable. It is notable that we were unable to rescue XM256 as a
homozygote with either transgene. This may be due to a closely
linked second mutation on the gene trap chromosome, but is more
likely due to an insufficiency of transgene expression at some critical
point indevelopment. Thisis supportedbythe reduced bodyweight
of XM256/C201R mice with transgene rescue despite full rescue of
viability and neurological function equivalent to a wild type allele.
Presumably, the C201R allele provides sufficient GARS activity in
whatever tissue may be lacking transgene expression, allowing
rescue of the point mutation over the gene trap. Thus, over-
expression ofwild-typeGARScanrescuepostnatal viability,butdoes
not improve the neuropathic phenotype, suggesting the loss of
viability is caused by a loss of function for which the transgene can
compensate, whereas the neuropathy is a gain of function that the
transgene cannot correct.
Figure 5. Wire hanging deficits in C201R/+ mice are not improved by over-expression of GARS. The severity of motor dysfunction in
C201R/+ mice was quantified using a wire hang test of grip strength. The mice were placed on a wire grid, which was then inverted and the latency to
fall was determined. The test was stopped at 60 seconds. Each mouse was evaluated in three trials with a 30 sec inter-trial interval. The means 6 SD
of the trials are plotted, and each point represents an individual animal. This test was performed at 3 weeks (A, C) and 6 weeks (B, D). Some wild-type
mice were noncompliant and failed to hang for the full 60 seconds. Mutants were never able to finish the task. Neither transgene improved the
behavioral deficits in C201R/+ mice at 3 or 6 weeks of age. (E, F) Nerve conduction velocities (NCVs) were also significantly reduced in this milder
CMT2D mouse model and this was not improved by either transgene. NCVs were measured at 12 weeks for mice crossed with transgene A and at 8
weeks for mice crossed with transgene D. (E) In the cross between C201R/+ mutant mice and transgene A the NCVs were: 36.165.4 for wild type
(n=6), 32.964.9 for WT; TgA (n=6), 21.169.4 for C201R/+ (n=5), and 20.763.8 for C201R/+; TgA mice (n=5). (F) In the cross between C201R/+ mutant
mice and transgene D, the NCVs were: 38.963.5 for wild type (n=2), 33.967.3 for WT; TgD (n=4), 17.361.9 for C201R/+ (n=5), and 22.662.5 for
C201R/+; TgD mice (n=6). Transgenes A and D did not significantly improve NCVs in C201R/+ mutant mice.
doi:10.1371/journal.pgen.1002399.g005
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PLoS Genetics | www.plosgenetics.org 10 December 2011 | Volume 7 | Issue 12 | e1002399Figure 6. Transgenes A and D restore viability to C201R/XM256 mice. Motor and sensory branches of the femoral nerves of rescued C201R/
XM256; Tg mice were isolated at 8 weeks of age and compared to littermate wild-type, XM256/+, and C201R/+ control mice. Toluidine blue stained
sections show that motor and sensory nerves from wild type (A, B) and XM256/+ mice (C, D) control mice are qualitatively similar to nerves from
C201R/+ (E, F), C201R/XM256; TgA (G, H), and C201R/XM256; TgD (I, J) mice. (K) Functionally, nerve conduction velocities in wild type and XM256/+ are
not significantly different (35.263.4 (n=7), and 35.564.2 (n=4), respectively). However, as anticipated, values are reduced in C201R/+ mice (20.561.9
(n=6), p,0.001). Conduction velocities in rescued C201R/XM256 mice were not significantly different than C201R/+ mice, but still significantly
reduced compared to wild type controls (p,0.001). Values were: C201R/XM256;TgA=25.760.9 (n=4) and C201R/XM256;TgD=20.962.7 (n=3). (L)
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(n=6), C201R/XM256;TgA=564614 (n=6), C201R/XM256;TgD=546617 (n=4). There were no significant differences in these values. Axon numbers in
the sensory branch of the femoral nerve were also unchanged between genotypes as follows: wild type=876650, XM256/+=859632, C201R/
+=830689, C201R/XM256;TgA=822649, C201R/XM256;TgD=803642. Animal numbers are the same as for motor axons except for wild type, where
n=7.
doi:10.1371/journal.pgen.1002399.g006
Figure 7. Neuromuscular junctions in rescued mice are similar to those in C201R/+ mice. Neuromuscular junctions (NMJs) in wild-type (not
shown) and XM256/+ (A) mice are mature pretzel-like structures. B) While most NMJs in C201R/+ mice are fully innervated, some NMJs are partially
denervated or fully denervated. In rescued C201R/XM256; TgA (C), and C201R/XM256; TgD (D) mice, NMJ morphology is similar to that of C201R/+mice,
with regions of denervation in some NMJs with neighboring NMJs that are fully innervated. NMJ occupancy was evaluated in these mice to
quantitatively determine the severity of the phenotype. (E) 98.561.5% (n=6) of NMJs were fully occupied in wild-type mice and 95.561.4% (n=6) in
XM256/+ mice. These were both significantly higher than the 57.0612.0% (n=6) of NMJs that were fully occupied in C201R/+ mice (p,0.001). The
percentage of fully innervated NMJs was 67.0614.3% (n=6) in rescued C201R/XM256; TgA mice and 64.069.8% (n=4) in C201R/XM256; TgD mice, and
was not signficantly different from C201R/+ mice.
doi:10.1371/journal.pgen.1002399.g007
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viability in homozygous C201R mice. The motor branch of the femoral nerve was used to assess the severity of the neuropathy in homozygous
and compound heterozygous mice at post-natal day 17. Motor nerves from wild-type (A), C201R/+(B), and Nmf249/+ (C), were compared to nerves
from C201R/C201R; TgD (D), C201R/Nmf249 (E), and C201R/Nmf249; TgD (F), which were smaller. The scale bar (shown in C) is 50 mm. The gross
observation that the motor nerves are smaller in the homozygous and compound heterozygous mutant mice was confirmed quantitatively. (G) Motor
nerve count averages were as follows: 543624 for wild type mice (n=8), 533620 for C201R/+ mice (n=7), 461636 for Nmf249/+ mice (n=5), 246658
for C201R/C201R; TgD mice (n=9), 233618 for C201R/Nmf249 mice (n=4), and 236642 for C201R/Nmf249; TgD mice (n=5). C201R/C201R; TgD, C201R/
Nmf249, and C201R/Nmf249; TgD mice had fewer motor axons than Nmf249/+ mice (p,0.001 for all three genotypes). There were no significant
differences among the three genotypes that are homozygous or compound heterozygous for Gars mutation. (H) Body weights were as follows: wild
type=10.761.4 g (n=7), C201R/+=9.761.5 (n=8), Nmf249/+=8.862.3 (n=5), C201R/C201R; TgD=3.860.7 (n=9), C201R/Nmf249 = 7.161.4 (n=4),
and C201R/Nmf249; TgD=5.662.5 (n=5). C201R/C201R; TgD, and C201R/Nmf249; TgD mice weighed less than C201R/+ mice (p,0.001, p,0.01,
respectively). C201R/Nmf249 mice weighed more than C201R/C201R; TgD mice (p,0.05) and were not significantly different from C201R/+ mice.
Plantaris muscles were removed from P17 pups for neuromuscular junction imaging (I-O). Green pre-synaptic staining is from NF and SV2 antibodies,
red post-synaptic staining is a-bungarotoxin. Nearly mature NMJs were seen in wild-type animals (I). As shown in Figure 3 and Figure 7, C201R/+ (J)
and Nmf249/+ (K) have abnormal NMJ morphology with areas of denervation in some NMJs and others that are fully denervated. More severe signs of
denervation were seen in C201R/C201R; TgD, C201R/Nmf249, and C201R/Nmf249; TgD mice. There was a wide range of dysmorphic NMJ pathology in
C201R/C201R; TgD mice. Some sections had mostly denervated NMJs (arrows) (L), while other areas had some partially innervated junctions
(arrowheads) (M). A similar mix of morphologies was seen with C201R/Nmf249 mice (N) and C201R/Nmf249; TgD mice (O). The scale of I-O is indicated
by the 28 mm bar in O. Scoring of neuromuscular junctions was performed to quantitatively compare the proportion of NMJs that were fully
innervated (green), partially innervated (yellow), and denervated (red) (P). In Nmf249/+ mice, 14.263.0% of NMJs were denervated. Significantly more
junctions were fully denervated in C201R/C201R; TgD mice where 56.267.5% of NMJs were denervated, and in and C201R/Nmf249; TgD mice where
38.268.0% of NMJs were denervated (p,0.001 for both comparisons). Compared to C201R/+ mice, where 2.862.4% of NMJs were denervated,
significantly more were denervated in C201R/Nmf249 mice where 26.868.7% of junctions were denervated, but this was not statistically different
from the Nmf249/+ mice. Compared to both C201R/Nmf249 and C201R/Nmf249; TgD mice, C201R/C201R; TgD mice had a greater proportion of
denervated NMJs (p,0.05, p,0.001, respectively).
doi:10.1371/journal.pgen.1002399.g008
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major determinant of disease severity
C201R homozygous mice have decreased viability, and when
they are born they have a severe neuropathy. We expected
C201R/Nmf249 mice to be at least as severe because the Nmf249
allele is more pathogenic than the C201R allele despite its normal
enzymatic activity. Surprisingly, the compound heterozygous mice
were as healthy as or even healthier than C201R homozygotes with
TgD. The C201R/Nmf249 mice were fully viable and weighed
significantly more than C201R/C201R; TgD mice, although their
neuropathy was markedly more severe than either allele as a
heterozygote. Therefore, the C201R and Nmf249 alleles are
capable of intragenic complementation in regard to the loss-of-
function phenotype, but still display ‘‘additive’’ severity for the
gain-of-function neuropathy phenotype. Over-expression of wild-
type GARS did not improve the phenotype in the compound
heterozygous mice, which are severely affected because they
express two mutant versions of the protein. This suggests that the
loss-of-function aspect of the C201R homozygotes that is rescued
by the transgene is not a factor in the compound heterozygotes,
and that the dose of the mutant protein determines the severity of
the neuropathy. It also suggests that this loss of function, perhaps
in enzyme charging function, differs between the alleles, because
C201R/Nmf249 mice are more viable than C201R/C201R mice
even though the Nmf249 allele is more neurotoxic than the C201R
allele.
Therapies for tRNA–synthetase–linked neuropathies
should selectively target the mutant allele
Dominant mutations in GARS, YARS, and AARS all cause CMT
[14–16]. Our results suggest that mutant forms of GARS adopt a
pathological function that may be impacting the normal role of
GARS in translation, but that the loss-of-function effects are
recessive, and would not be an important factor in CMT patients
with dominantly inherited disease. Instead, the neuropathy is a
caused by a gain of function, demonstrated by the inability of
functional wild-type transgenic GARS to rescue the phenotype
either by restoring lost activity or outcompeting this pathological
function. One patient reported to carry compound heterozygous
mutations in KARS may be the exception to this, but it is notable
that this genotype was associated with peripheral neuropathy
with additional neurological and non-neurological symptoms
[17].
The interplay between normal protein function and pathogenic
function has been dissected in other neurodegenerative diseases.
For example, hereditary sensory and autonomic neuropathy
(HSAN) type 1A is caused by mutations in the serine palmitoyl
transferase gene (SPTLC1), which alter the protein’s amino acid
substrate specificity so that the mutant produces two neurotoxic
atypical deoxysphingoid bases [33–35]. Over-expression of wild-
type SPTLC1 rescued a transgenic mouse model of the disease by
outcompeting mutant forms of SPTLC1 in heterodimer formation
with SPTLC2, restoring the substrate specificity, lowering levels of
neurotoxic sphingoid bases, and demonstrating that mutant
SPTLC1 is not inherently toxic [36]. Our work suggests that
mutant GARS protein is toxic independent of wild-type protein
levels. These results are more like what has been observed in
SOD1-linked amyotrophic lateral sclerosis, which is caused by
dominant mutations and is not improved with wild-type over-
expression [37].
These conclusions have implications for therapeutic approach-
es. To reduce the effect of mutant GARS, the expression of the
mutant allele must be diminished. Future therapeutic approaches
should focus on allele specific knockdown of the mutant gene
expression; alternatively, the specific pathways affected by mutant
GARS toxicity could be identified and targeted.
Materials and Methods
Generation of transgenic mice
The Ins-CMV-C-B-A vector [38] was modified to include a
Gateway conversion cassette (Invitrogen) in the multiple cloning
site, which includes a ccdB cassette flanked by attR1 and attR2
recombination sequences. A Gateway LR clonase reaction was
used to insert a PCR amplicon of the GARS cDNA (human) into
the pINS2-Gateway vector. The cDNA amplicon that was inserted
into pINS2 included 47 basepairs of the endogenous GARS 59
UTR upstream of the start site of the mitochondrial isoform, and
19 basepairs of endogenous 39UTR flanked by 59 and 39
untranslated regions (UTR) from rabbit b globin also containing
a polyadenylation signal at the 39 end. The cDNA and control
elements are flanked by two chicken b-globin 59HS4 insulators,
which have been shown to reduce variability in transgene
expression caused by position effects of insertion site [39].
Pronuclear injection of this construct into single cell FVB/N
embryos was performed in the NHGRI Transgenic Mouse Core
according to existing protocols [40].
Mouse strains, husbandry, and genotyping
All mouse husbandry and procedures were conducted according
to the NIH Guide for Care and Use of Laboratory Animals and
were approved by NINDS or The Jackson Laboratory Animal
Care and Use Committee. Tail, toe or ear tissue was lysed with
proteinase K incubation at 55uC and boiled for 10 min to
inactivate the proteinase K. DNA derived from the mouse tissue
was then used in PCR to determine genotype.
Table 1. A summary of the genotypes of mice used in these
studies indicating the viability and neuropathy phenotypes
associated with each genotype.
Genotype Viability Neuropathy
Gars
+/+ normal 2
Gars
+/+;T g A normal 2
Gars
+/+;T g D normal 2
Gars
Nmf249/+ normal +++
Gars
Nmf249/+;T g A normal +++
Gars
Nmf249/+;T g D normal +++
Gars
C201R/+ normal ++
Gars
C201R/+; TgA normal ++
Gars
C201R/+; TgD normal ++
Gars
XM256/+ normal 2
Gars
C201R/XM256 embryonic lethal ND
Gars
C201R/XM256;T g A normal ++
Gars
C201R/XM256;T g D normal ++
Gars
C201R/C201R reduced viability ND
Gars
C201R/C201R;T g D normal viability, reduced lifespan (P17) ++++
Gars
C201R/Nmf249 normal viability, reduced lifespan ++++
Gars
C201R/Nmf249;T g D normal viability, reduced lifespan ++++
KEY: ND none determined, 2 normal phenotype, ++ moderate, +++ severe,
++++ very severe.
doi:10.1371/journal.pgen.1002399.t001
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GATCTA-39) and GARS WT Tg R (59-TTTCCGAGCG-
GACTGTCCGC-39), which anneal to exons 7 and 9, respectively,
were used to determine if the wild-type transgene was present.
Primers targeting Gars intron 6F (59-GCCTTGTTCTGTA-
ACGTTTGCAC-39) and a primer specific to the Nmf249 allele
(59-CCAGGCATATTTCCTCCATATTT-39) were used to iden-
tify mice with the Nmf249 mutation [25]. Primers Gars C201R F
(59-CACGTGCTTGCTCTAGCAAGA-39) and Gars C201R R
(59-GTCTACCACTGAACACAGTCC-39) were used in PCR
reaction, and the product was digested with HhaI restriction
enzyme. PCR products containing the pathogenic mutation are
digested into two smaller bands [26]. Primers BgeoR (59-CG-
CCAGGGTTTTCCCAGT-39) and En2-i1F (59-AATGCCCAA-
CACTTGTATGG-39) were used to determine if the XM256 gene
trap allele was present. To screen for XM256/XM256 mice,
primers flanking the gene trap insertion 519 bp into intron 2 of
Gars, GarsXMvsWT2F (59-GCTTCCGCACTACCTGAACCC-
AAACT-39) and GarsXMvsWT2R (59-TGAATTCAGCAGC-
CCCCTCTGTACCC-39), were used. No XM256/XM256 mice
were identified, with or without the transgene. PCR amplification
indicated the wild-type allele was present. All genotyping products
were resolved on 2% agarose gels with ethidium bromide (Sigma,
St. Louis, MO). Nmf249 mice are maintained on a C57BL/6
background and are occasionally outcrossed to CAST/Ei to
improve their ability to breed [21]. C201R mice were originally on
a mixed C57BL/6 and C3H background and subsequently bred
into a C57BL/6 background. The TgA and TgD alleles were
maintained on a pure FVB/N background with one exception: the
TgA mice that were used in the cross with C201R mice were on a
FVB/N X C57BL/6 F1 hybrid background. Therefore, experi-
ments were done primarily in a [FVB/N X BL/6] F1 background
unless two matings were required to generate homozygotes or
compound heterozygotes, in which case mice were effectively in an
[N2] C57BL/6 background. All control animals were siblings of
the experimental genotypes.
Tissue lysate preparation
Spinal cord and sciatic nerve were isolated from animals
immediately after they were euthanized by CO2 inhalation. The
tissues were frozen in liquid nitrogen and stored at 280uC. The
tissues were then homogenized in 1% NP-40 in phosphate
buffered saline (PBS) supplemented with Protease Inhibitor
Cocktail Tablets (Roche, Basal, Switzerland) using a PowerGen
Model 125 Homogenizer (Fisher Scientific, Pittsburgh, PA) then
centrifuged at 14,000 g for 10 min at 4uC. Cleared homogenates
were then sonicated at 4uC and centrifuged again at 14,000 g for
10 min. Protein concentrations were assessed using a Bradford
assay (BioRad, Hurcules, CA). 20 mg of protein was then analyzed
by immunoblot.
Western blots
Protein lysates were resolved on Novex 10% Tris-Glycine Gels
(Invitrogen, Carlsbad, CA) and transferred to an Invitrolon PVDF
membrane for western blot analysis. Membranes were blocked
with 5% skim milk in TBST (16 Tris-buffered saline, 0.1%
Tween-20), and incubated overnight with GARS rabbit polyclonal
antibody ab42905 (1:2,000) (Abcam, Cambridge, MA) and b actin
mouse monoclonal antibody clone AC-74 (1:10,000)(Sigma
Aldrich, St. Louis, MO) diluted in blocking solution at 4u C.
Following three 10 min washes in TBST, the blots were incubated
with the appropriate horseradish peroxidase-conjugated secondary
antibodies (Jackson ImmunoResearch, West Grove, PA) diluted in
blocking solution. After three 10-min washes in TBST, the blots
were developed using Western Lightening Plus-ECL, Enhanced
Chemiluminescence Substrate (Perkin Elmer, Waltham, MA).
Teased nerve immunohistochemistry
Teased nerve fibers were stained as described in the methods of
[21,41]. In brief, sciatic nerves were excised, immediately placed
in fresh 4% paraformaldehyde, and fixed on ice for 15 minutes.
Nerves were then transferred to ice cold PBS for dissection and
teasing. Using #5 forceps and 30 gauge needles, nerve sheaths
were removed and the nerves were cut into 1 cm segments and
teased apart at one end. The nerve segments were then transferred
to a fresh Superfrost Plus Gold slides (Fisher Scientific, Pittsburgh,
PA) and pulled from a drop of PBS onto a dry section of the slide
to straighten the fibers for imaging. The slides were then dried
overnight at room temperature and incubated in acetone at
220uC for 10 min. The samples were then rehydrated with two
5 min incubations in PBS and blocked with 5% normal goat
serum in PBS with 0.5% Triton X-100 for 1 h at room
temperature. Primary antibodies rabbit anti-GARS (1:500)
(Abcam), mouse anti-neurofilament with the 2H3 antibody
(1:500)(Developmental Studies Hybridoma Bank, Iowa City, IA)
were gently placed on the slide, covered with Parafilm coverslips
(Pechinery Plastic, Chicago, IL) and stored in a humidified
chamber overnight at 4u Celsius. After three 5-min washes in PBS,
the samples were incubated in the following secondary antibodies
diluted 1:1,000 in blocking solution: AlexaFluor 555 goat anti-
rabbit, and AlexaFluor 488 goat anti-mouse IgG1 (y1) (Invitrogen,
Carlsbad, CA). The samples were covered with Parafilm coverslips
and incubated for 2 h at room temperature. The samples were
then washed three times in PBS for 5 min each in watch glasses
and mounted with Vectashield (Vector Labs, Burlingame, CA).
Aminoacylation assays
Aminoacylation assays were performed at room temperature in
a reaction mixture containing 50 mM HEPES (pH 7.5), 20 mM
KCl, 2 mM ATP, 5 mM MgCl2, 1 mM DTT, 19 mM L-glycine
(or L-alanine), 1 mM
3H-L-glycine (or
3H-L-alanine), 2 mM
transcribed human tRNA
Gly
CCC [for GlyRS activity] or 120 mM
yeast total tRNA (Roche Diagnostics, Indianapolis, IN) [for AlaRS
activity] and 30 mg total protein from tissue homogenates.
Reactions were initiated by addition of reaction mixture and
tRNA to tissue homogenates. Aliquots were quenched at different
time points and precipitated in 96-well Multiscreen filter plates
(Millipore) as described previously [42]. After washing and elution
by NaOH, samples were counted in a MicroBeta plate reader
(PerkinElmer Life Sciences). Initial rates were measured from
slopes obtained by fitting the data to a non-linear regression curve
using GraphPad Prism 5 software. For TgA, 3 wild type and 4
transgenic littermates were sampled at 9 weeks of age: for TgD, 4
wild type and 3 transgenic littermates were tested at 6 weeks of
age.
Motor and sensory nerve analysis
The sensory and motor branches of the femoral nerve were
isolated and fixed overnight in 2% glutaraldehyde and 2%
paraformaldehyde in a 0.1 M cacodylate buffer. The tissue was
then processed for transmission electron microscopy and embed-
ded in plastic before 0.5 mm sections were cut and stained with
toluidine blue. For more information see [43]. For axon counting
and axon diameter measurement the images were captured using a
Nikon Eclipse E600 microscope with 406 and 1006 objectives.
Axon counts were done using the Cell Counter Plug-in in ImageJ.
Left and right nerves were averaged. Axon diameters were
measured using the Measure and Label Plugin, also in ImageJ.
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Mouse plantaris muscles were surgically removed and fixed in
freshly prepared 2% paraformaldehyde in PBS for four hours. The
samples were then transferred to a blocking and permeabilizing
solution of 5% normal goat serum and 0.5% Triton-X 100 in PBS
for 1 h before they were pressed between two glass slides using a
binder clip for 15 min, after which they were returned to the
blocking and permeabilizing solution. The samples were then
incubated overnight at 4uC with 1:1,000 dilutions of anti-SV2 and
anti-neurofilament (2H3) primary antibodies (Developmental
Studies Hybridoma Bank, Iowa City, IA). After at least three
1 h washes in PBS with 0.5% Triton-X 100, the samples were
transferred to blocking and permeabilizing solution with Alexa-
Fluor 488 goat anti-mouse IgG1 (y1) (Invitrogen, Carlsbad, CA)
and a-bungarotoxin conjugated with Alexa Fluor 594. After
incubation overnight at 4uC, the samples were washed three times
for 1 h each and mounted with Vectashield mounting media
(Vector Labs, Burlingame, CA) and imaged using a confocal
microscope.
Confocal microscopy
Confocal images were gathered using a Carl Zeiss LSM 710 or
Leica SP5 laser-scanning confocal microscope with a 636
objective. Z stacks were collapsed into projected images and
merged using ImageJ (NIH, http://rsb.info.nih.gov/ij/). The
color balance of the NMJ images was adjusted for clarity.
Nerve conduction studies
Sciatic nerve conduction velocity was calculated by measuring
the latency of compound motor action potentials recorded in the
muscle of the left rear paw. The mice were anesthetized with 1%
isofluorane and placed on a thermostatically regulated heating pad
to maintain normal body temperature. Action potentials were
produced by subcutaneous stimulation at the sciatic notch and at
the ankle. For recording, the active needle electrode was inserted
in the center of the paw and a reference electrode was placed in
the skin between the first and second digits.
Statistical analysis
Statistical tests were performed using GraphPad’s Prism 5
software. Statistical significance was determined using a one-way
ANOVA and a post hoc Tukey test for individual differences when
appropriate. A threshold of p,0.05 was considered significant.
The use of other tests is noted in the text. All results are presented
as means 6 SD.
Supporting Information
Figure S1 GARS expression was assayed by western blot for all
of the crosses performed in this study. Spinal cord and sciatic nerve
tissues from two mice in each genotype were analyzed for GARS
expression levels by western blot: b actin was used as a loading
control.
(TIF)
Figure S2 Myelin thickness and axon diameter in motor nerves
are not affected by transgene A or D. The diameter and myelin
thickness of 100 axons were measured and averaged in each
animal. The axon diameter data is the mean of the data presented
as a cumulative histogram in Figure 2. Axon diameter averages
were as follows: wild type=3.760.3 (n=6), WT; TgA=3.660.3
(n=6), WT; TgD=3.760.4 (n=6), Nmf249/+=1.960.8 (n=5),
Nmf249/+; TgA=2.060.9 (n=5), and Nmf249/+; TgD 2.160.1
(n=3). Myelin thickness averages were as follows: wild
type=1.0560.10 (n=6), WT; TgA=1.1360.13 (n=6), WT;
TgD=1.2060.08 (n=6), Nmf249/+=0.8560.11 (n=5),
Nmf249/+; TgA=0.9260.12 (n=5), and Nmf249/+; TgD
0.8760.02 (n=3).
(PDF)
Figure S3 Rescued mice weigh less than wild type, but muscles
are not unduly atrophied. Wild-type mice at 8 weeks of age
weighed 23.864.0 (n=10) and XM256/+ mice weighed 22.965.0
(n=8). Neither of these was significantly different from C201R/+
mice, which weighed 21.162.3 g (n=4). Wild-type mice were
heavier than the rescued C201R/XM256; TgA mice, which
weighed 16.062.4 (n=6), and C201R/XM256; TgD mice, which
weighed 14.262.0 (n=4) (p,0.01). (B) Rescued mice did not have
significantly different ratios of muscle weight to body weight, a
measure of muscle-specific atrophy. This shows that muscles in
C201R/XM256; TgA and C201R/XM256; TgD mice are not
smaller than muscles in C201R/+ or controls relative to their total
body mass. Two plantaris muscles were weighed and compared to
the body weight of male mice in this cross. The muscle (mg) to
bodyweight (g) ratios were as follows: the wild-type ratio was
1.6960.14 (n=4), the XM256/+ ratio was 1.6260.11 (n=6), the
C201R/+ ratio was 1.33+0.09 (n=4), the C201R/XM256; TgA
ratio was 1.5660.14 (n=4), and the C201R/XM256; TgD ratio
was 1.5160.07 (n=3), indicating that muscles are not smaller than
anticipated for body weight, and that no neurogenic atrophy is
evident.
(PDF)
Figure S4 Sensory neuropathy is similar in severity to motor
neuropathy in C201R/C201R; TgD, C201R/Nmf249, and C201R/
Nmf249; TgD mice. Femoral sensory nerve sections from wild type,
C201R/+, and Nmf249/+ littermate controls (A–C) are noticeably
larger than sections from C201R/C201R; TgD, C201R/Nmf249,
and C201R/Nmf249; TgD mice (D–F). The scale bar for A–F is in
C and is 50 mm. G) Quantitative analysis confirmed this
qualitative difference. Sensory nerve counts were as follows:
811692 for wild-type mice (n=7), 846683 for C201R/+ mice
(n=6), 865679 for Nmf249/+ mice (n=5), 3146112 for C201R/
C201R; TgD mice (n=8), 289674 for C201R/Nmf249 mice (n=4),
and 2446102 for C201R/Nmf249; TgD mice (n=5). C201R/
C201R; TgD, C201R/Nmf249, and C201R/Nmf249; TgD mice had
significantly fewer sensory axons than wild-type controls (p,0.001
for all three genotypes). These observations parallel the motor
axon count differences seen in C201R/C201R; TgD, C201R/
Nmf249, and C201R/Nmf249; TgD mice. Note that the change in
the normal axon number in Nmf249/+ sensory nerves is likely to
be due to the younger age (P17) at which there mice were
examined.
(TIF)
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